If you smoke cannabis you aren't getting much carboxylic acid cannabinoids at all, for sure nowhere near the amount required to hit micromolar concentrations at an in vivo receptor. Actually the same with CBD because its such a minor component.
I definitely won't argue about the numerous cannabinoids having an assortment of medical uses, but based on my knowledge of behavior and pharmacology the likely mechanism of people avoiding COVID when using cannabinoids for their psychoactive effect is the change in behavior rather than a direct pharmacological action affecting some mechanism of SARS-Cov-2. If its even related at all and not just anecdotal correlation, which is a seriously major possibility
I commented on a comment about using cannabis for the psychoactive effects very specifically, rather than commenting what I stated on the article itself
Now onto the article you posted, I just finished checking it over and I have some concerns.
First, considering this is a supposed pharmacological study I don't see concentrations of active compounds (THC or CBD) listed anywhere. These would be listed as something like uM or nM for micro or nanomolar. Perhaps I missed them and I'm open to anyone pointing out these values to me.
Secondly, this is a preprint study and when you look at the bottom under "competing interests" you can see that it was funded/performed by a cannabis company with skin in the game.
I'm not saying write it off entirely, but I'm very suspicious of the study for these reasons.